Method for determining the survival prognosis of a patient suffering from pancreatic cancer
AssigneeAcobiom
InventorDavid PIQUEMAL
Life of this patent
Estimating the term…
Abstract
The present invention relates to pancreatic cancer, and more particularly to the survival prognosis of a patient suffering from pancreatic cancer. The invention also aims to determine the suitability of said patient to receive a treatment for pancreatic cancer, in particular a treatment with gemcitabine. The invention also concerns a method for monitoring the effectiveness of a treatment for pancreatic cancer, and advantageously a treatment with gemcitabine, by implementing the method.
Claims28
In-vitro method for establishing a survival prognosis for a patient suffering from pancreatic cancer, comprising the following steps:
- a) measuring the level of expression of at least one marker gene selected from the group constituted by the NME4, ITPR3, SESN3, ARL4C and RPLP1 genes or homologous genes, in a blood sample taken previously from said patient;
- b) comparing the level of expression measured for the marker gene(s) selected in step a) in said patient against a reference threshold;
- c) evaluating the survival time for said patient.
In-vitro method for predicting or evaluating the efficacy and/or benefit of treatment of pancreatic cancer in a patient suffering from said pathology, comprising the following steps:
- a) measuring the level of expression of at least one marker gene selected from the group constituted by the NME4, ITPR3, SESN3, ARL4C and RPLP1 genes or homologous genes, in a blood sample taken previously from said patient;
- b) comparing the level of expression measured for the marker gene(s) selected in step a) in said patient against a reference threshold;
- c) evaluating the survival time for said patient.
Gemcitabine for use for treating pancreatic cancer in a patient who has an INDEXpatient less than 1.102, INDEXpatient being determined by an in-vitro method comprising the following steps:
- a) measuring the level of expression of a combination of the five marker genes NME4, ITPR3, SESN3, ARL4C and RPLP1 and of two ubiquitous B2M and GADPH genes in a blood sample taken previously from said patient, the level of expression of the genes corresponding to the transcription level of the RNA or cDNA of said genes, measured as number of cycle(s) (Ct, “cycle threshold”) by real-time quantitative PCR (qPCR), the level of expression of the five marker genes then being normalized with respect to the level of expression of the ubiquitous genes according to
- ΔCtgene=Ctgene−[mean value of the Ctubiquitous genes]
- to obtain a normalized level of expression ΔCtgene for each of the five marker genes,
- b) comparing the level of expression measured for the marker genes selected in step a) in said patient and for each gene the expression of which has been measured:
- i) a value INDEXgene is determined, which is dependent on the normalized level of expression of the gene, defined by:
- INDEXgene=+1*β coefficient of the gene, if ΔCtgene>reference threshold of the gene, and
- INDEXgene=−1*β coefficient of the gene, if ΔCtgene<reference threshold of the gene, and
- in which the β coefficient and the reference threshold (Sref) of a given gene are as defined below
- Gene
- Sref
- β coefficient
- NME4
- 3.1864
- −1.3207
- ITPR3
- 6.4014
- 1.0850
- SESN3
- 3.6262
- 1.0301
- ARL4C
- 2.6286
- 1.3577
- RPLP1
- 6.3748
- 1.0101
- ii) a value INDEXpatient, equal to the sum of the INDEXgene of the genes of the combination, is determined for a given patient, and
- iii) INDEXpatient is compared against the final reference threshold of 1.102;
- c) evaluating the survival time for said patient, an INDEXpatient less than 1.102 indicating a prognosis of long-term survival.
Kit for determining the prognosis of pancreatic cancer in a patient, comprising means for detecting the level of expression of at least two genes selected from the group constituted by NME4, ITPR3, SESN3, ARL4C and RPLP1, advantageously for detecting the level of expression of all 5 genes NME4, ITPR3, SESN3, ARL4C and RPLP1.
Use of at least one gene selected from the group constituted by the NME4, ITPR3, SESN3, ARL4C and RPLP1 genes or homologous genes, or of the combination of the 5 genes or homologous genes, for prognosis of pancreatic cancer, in a patient.
Use of at least one gene selected from the group constituted by the NME4, ITPR3, SESN3, ARL4C and RPLP1 genes or homologous genes, or of the combination of the 5 genes or homologous genes, for monitoring the efficacy of a treatment for pancreatic cancer, advantageously treatment with gemcitabine in a patient.
Dependencies are inferred from the claim text.